Medicare Enrolled
Dr. Dong Xiang, MD
Hematology · San Gabriel, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Xiang from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Xiang?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Xiang
Dr. Dong Xiang is a hematology specialist in San Gabriel, CA, with 18 years of NPI registration. Based on federal Medicare data, Dr. Xiang performed 3,006 Medicare services across 450 unique beneficiaries.
Between the years covered by Open Payments, Dr. Xiang received a total of $71,263 from 84 pharmaceutical and/or device companies across 952 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Xiang is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice
▲ Top 15% volume in CA
$71,263 industry payments
Medicare Practice Summary
Medicare Utilization ↗3,006
Medicare services
Top 15% in CA for hematology
450
Unique beneficiaries
$24
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~167 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Anti-nausea injection (ondansetron/Zofran) | 1,064 | $0 | $1 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
830 | $0 | $2 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
246 | $93 | $313 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
110 | $114 | $366 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
94 | $13 | $52 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
86 | $25 | $79 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
81 | $10 | $50 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
77 | $1 | $5 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
73 | $8 | $29 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
73 | $100 | $226 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
58 | $57 | $177 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
43 | $51 | $194 |
| New patient office visit, complex (60-74 min) | 41 | $171 | $672 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
27 | $59 | $201 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
27 | $147 | $501 |
| Office visit for established patient An office visit for an existing patient that may not require the healthcare professional to be present. |
25 | $19 | $81 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
21 | $54 | $190 |
| Telephone medical discussion, 21-30 minutes A telephone conversation with a physician lasting between 21 and 30 minutes. This code covers the time spent discussing medical matters over the phone. |
16 | $83 | $266 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
14 | $145 | $413 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
11.7% high complexity
66.1% medium
22.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$71,263
Total received (2018-2024)
Avg $10,180/year across 7 years
Top 19% in CA for hematology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
84
Companies
952
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$40,807 (57.3%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$17,797 (25.0%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$12,360 (17.3%)
Other
Charitable contributions, space rental, and other categories
$299 (0.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$8,923
2023
$32,863
2022
$14,533
2021
$3,177
2020
$1,143
2019
$9,871
2018
$751
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
BeiGene USA, Inc.
$3,888
Regeneron Healthcare Solutions, Inc.
$2,804
AstraZeneca Pharmaceuticals LP
$347
Astellas Pharma US Inc
$162
Tempus AI, Inc
$149
Merck Sharp & Dohme LLC
$145
PFIZER INC.
$139
Gilead Sciences, Inc.
$138
ABBVIE INC.
$130
Eisai Inc.
$107
SOBI, INC
$102
Celgene Corporation
$100
Genentech USA, Inc.
$85
ADC Therapeutics America, Inc.
$74
GlaxoSmithKline, LLC.
$66
Janssen Biotech, Inc.
$58
Takeda Pharmaceuticals U.S.A., Inc.
$48
Genmab U.S., Inc.
$44
Lilly USA, LLC
$42
Daiichi Sankyo Inc.
$42
Sumitomo Pharma America, Inc.
$41
Janssen Scientific Affairs, LLC
$37
Myriad Genetic Laboratories, Inc.
$37
Incyte Corporation
$26
JAZZ PHARMACEUTICALS INC.
$21
PROGENICS PHARMACEUTICALS, INC.
$21
Novartis Pharmaceuticals Corporation
$19
Bayer Healthcare Pharmaceuticals Inc.
$19
E.R. Squibb & Sons, L.L.C.
$16
Blueprint Medicines Corporation
$15
Top 3 companies account for 78.9% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$17,917
Seagen Inc.
$12,930
Novocure Inc.
$6,938
Janssen Biotech, Inc.
$4,281
Seattle Genetics, Inc.
$4,275
BeiGene USA, Inc.
$4,079
Regeneron Healthcare Solutions, Inc.
$3,321
PFIZER INC.
$1,082
Novartis Pharmaceuticals Corporation
$1,063
Amgen Inc.
$1,056
Incyte Corporation
$1,024
Merck Sharp & Dohme LLC
$813
Celgene Corporation
$735
GENZYME CORPORATION
$692
GlaxoSmithKline, LLC.
$680
Astellas Pharma US Inc
$668
E.R. Squibb & Sons, L.L.C.
$582
Gilead Sciences, Inc.
$579
Takeda Pharmaceuticals U.S.A., Inc.
$551
Lilly USA, LLC
$519
Exelixis Inc.
$449
Karyopharm Therapeutics Inc.
$412
Rigel Pharmaceuticals, Inc.
$341
Eisai Inc.
$318
Pharmacyclics LLC, An AbbVie Company
$305
NOVARTIS PHARMACEUTICALS CORPORATION
$299
Alexion Pharmaceuticals, Inc.
$278
Daiichi Sankyo Inc.
$273
Bayer HealthCare Pharmaceuticals Inc.
$250
Boehringer Ingelheim Pharmaceuticals, Inc.
$244
Genentech USA, Inc.
$242
Merck Sharp & Dohme Corporation
$237
Sobi, Inc
$234
AbbVie Inc.
$220
ADC Therapeutics America, Inc.
$219
Bayer Healthcare Pharmaceuticals Inc.
$200
SANOFI-AVENTIS U.S. LLC
$199
Puma Biotechnology, Inc.
$178
ABBVIE INC.
$173
PharmaEssentia USA Corporation
$172
Mirati Therapeutics, Inc.
$167
SOBI, INC
$167
EMD Serono, Inc.
$158
Tempus AI, Inc
$149
Myovant Sciences Inc.
$94
Blueprint Medicines Corporation
$88
EISAI INC.
$84
Pharmacyclics LLC, an AbbVie Company
$81
TerSera Therapeutics LLC
$80
Stemline Therapeutics Inc.
$78
TOLMAR Pharmaceuticals, Inc.
$76
Dova Pharmaceuticals
$63
Sumitomo Pharma America, Inc.
$57
Foundation Medicine, Inc.
$52
Dendreon Pharmaceuticals LLC
$52
Janssen Scientific Affairs, LLC
$50
JAZZ PHARMACEUTICALS INC.
$49
Genmab U.S., Inc.
$44
Agios Pharmaceuticals, Inc.
$42
Apellis Pharmaceuticals, Inc.
$40
MorphoSys, US Inc.
$38
Myriad Genetic Laboratories, Inc.
$37
Deciphera Pharmaceuticals Inc.
$34
Ipsen Biopharmaceuticals, Inc
$34
EUSA Pharma (US) LLC
$32
ImmunoGen, Inc.
$28
ARRAY BIOPHARMA INC
$26
Taiho Oncology, Inc.
$25
GE HEALTHCARE
$24
Organon LLC
$24
GE HealthCare
$23
PUMA BIOTECHNOLOGY, INC.
$23
Novo Nordisk Inc
$23
PROGENICS PHARMACEUTICALS, INC.
$21
Jazz Pharmaceuticals Inc.
$21
Heron Therapeutics, Inc.
$20
Coherus Biosciences Inc.
$20
RECORDATI_RARE_DISEASES_INC.
$20
G1 Therapeutics, Inc.
$18
Mylan Institutional Inc.
$16
INSYS Therapeutics Inc
$15
Optos, Inc.
$14
Acrotech Biopharma LLC
$14
Tolmar, Inc.
$13
Top 3 companies account for 53.0% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · ALUNBRIG · AYVAKIT · Alecensa · BAVENCIO · BELEODAQ · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Balversa · Bavencio · CABLIVI · CABOMETYX · CALQUENCE · CARVYKTI · CHANTIX · COSELA · CREON · CYRAMZA · Cabometyx · Columvi · DARZALEX · DOPTELET · Doptelet · ELIGARD · ELIQUIS · ELITEK · ENHERTU · ENJAYMO · EPKINLY · ERBITUX · ERLEADA · Elahere · Empaveli · Enhertu · Epkinly · Erleada · Esperoct · FASLODEX · FOUNDATIONONE · FRUZAQLA · GAMIFANT · GAVRETO · GILOTRIF · Halaven · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Imbruvica · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · LIBTAYO · LONSURF · LUMAKRAS · LUPRON DEPOT · LUTATHERA · LYNPARZA · Lenvima · MEKINIST · MONJUVI · MVASI · MYLOTARG · MYRISK · NERLYNX · NINLARO · Nerlynx · Nexavar · Non-Covered · Nplate · Nubeqa · ONTRUZANT · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · Ogivri · Oncology · Onivyde · Optune · Orserdu · PADCEV · PANORAMIC OPHTHALMOSCOPE · PEMAZYRE · PIQRAY · PRECISETUMOR · PROMACTA · PROVENGE · PYLARIFY · Perjeta · Phesgo · Pomalyst · Prolia · QINLOCK · Quzyttir · REBLOZYL · RETEVMO · Revlimid · Rezlidhia · SARCLISA · SCEMBLIX · SOLIRIS · SOMATULINE DEPOT · SPRYCEL · SYLVANT · SYNDROS · Stivarga · Sustol · Sylvant · TABRECTA · TAGRISSO · TASIGNA · TECVAYLI · TIBSOVO · TIVDAK · TUKYSA · Tavalisse · Tecentriq · Trodelvy · ULTOMIRIS · Udenyca · Ultomiris · VELCADE · VENCLEXTA · VERZENIO · VONJO · Vemlidy · Venclexta · XALKORI · XGEVA · XOSPATA · XPOVIO · XTANDI · XYNTHA · Xermelo · Xofigo · Xospata · Xtandi · ZEJULA · ZEPZELCA · Zoladex
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (57%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Geographic Context
Hematologists within 10 mi
38
Per 100K population
0.4
County median income
$87,760
Nearest hospital
SAN GABRIEL VALLEY MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Xiang is a mixed practice specialist, with above-average Medicare volume (top 15% in CA), with consulting-driven industry engagement in the top 19% of CA peers, with 18 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Xiang experienced with anti-nausea injection (ondansetron/zofran)?
Based on Medicare claims data, Dr. Xiang performed 1,064 anti-nausea injection (ondansetron/zofran) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Xiang receive payments from pharmaceutical companies?
Yes. Dr. Xiang received a total of $71,263 from 84 companies across 952 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Xiang's costs compare to other hematologists in San Gabriel?
Dr. Xiang's average Medicare payment per service is $24. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Xiang) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematologists in San Gabriel
Browse hematologists in San Gabriel ranked by procedure volume and transparency data.
Highest volume
Top Hematologists in CA
Hematologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematologists in CA
Which CA hematologists receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Seagen Inc. Payments to Doctors
See all physicians who received payments from Seagen Inc.
By company
Novocure Inc. Payments to Doctors
See all physicians who received payments from Novocure Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology